Search research articles
Contact Us
Filters
Showing results (101-110 of 114) with videos related to
Page
of 12
Sort By:
Science Translational Medicine
|
December 9, 2016
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
Jacalyn Rosenblatt, Richard M Stone, Lynne Uhl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A Holstein, Alan Howard, David Avigan, et al.
The New England Journal of Medicine
|
July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Lancet (London, England)
|
June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Cancer Research Communications
|
March 27, 2023
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
Lijun Yao, Reyka G Jayasinghe, Brian H Lee, et al.
Blood Cancer Discovery
|
December 9, 2025
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma
Denis J Ohlstrom, William C Pilcher, Marina E Michaud, et al.
Journal for Immunotherapy of Cancer
|
December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Michael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 114) with videos related to
Sort By:
Page
of 12
Science Translational Medicine
|
December 9, 2016
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
Jacalyn Rosenblatt, Richard M Stone, Lynne Uhl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A Holstein, Alan Howard, David Avigan, et al.
The New England Journal of Medicine
|
July 14, 2016
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S Davids, Haesook T Kim, Pavan Bachireddy, et al.
Lancet (London, England)
|
June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
David J Chung, Nina Shah, Juan Wu, et al.
Cancer Research Communications
|
March 27, 2023
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
Lijun Yao, Reyka G Jayasinghe, Brian H Lee, et al.
Blood Cancer Discovery
|
December 9, 2025
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma
Denis J Ohlstrom, William C Pilcher, Marina E Michaud, et al.
Journal for Immunotherapy of Cancer
|
December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Michael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Page
of 12